46,378 Shares in Becton, Dickinson and Company $BDX Acquired by Midwest Trust Co

Midwest Trust Co bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 46,378 shares of the medical instruments supplier’s stock, valued at approximately $7,989,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at $26,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Becton, Dickinson and Company during the 1st quarter worth about $31,000. Bank of Jackson Hole Trust increased its holdings in shares of Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the last quarter. WPG Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $36,000. Finally, CVA Family Office LLC lifted its stake in Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 97 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the sale, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 1,249 shares of company stock worth $231,358. 0.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

BDX has been the topic of several recent analyst reports. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Jefferies Financial Group dropped their target price on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday. Finally, Piper Sandler decreased their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $203.27.

Becton, Dickinson and Company Stock Up 0.3%

Shares of NYSE:BDX opened at $177.88 on Monday. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The stock has a market cap of $50.99 billion, a P/E ratio of 31.99, a P/E/G ratio of 1.42 and a beta of 0.25. The firm has a fifty day moving average price of $186.77 and a 200 day moving average price of $182.15.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion during the quarter. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 71.36%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.